Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Zurich Insurance Group Ltd FI

Zurich Insurance Group Ltd FI cut its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 26.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 178,396 shares of the biotechnology company’s stock after selling 65,156 shares during the period. Axon Enterprise comprises approximately 0.9% of Zurich Insurance Group Ltd FI’s holdings, making the stock its 23rd biggest position. Zurich Insurance Group Ltd FI’s holdings in Axon Enterprise were worth $106,024,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of AXON. Perigon Wealth Management LLC acquired a new stake in Axon Enterprise in the 4th quarter worth about $488,000. Geneos Wealth Management Inc. boosted its holdings in Axon Enterprise by 630.0% in the 4th quarter. Geneos Wealth Management Inc. now owns 1,847 shares of the biotechnology company’s stock worth $1,098,000 after buying an additional 1,594 shares during the last quarter. Chicago Capital LLC boosted its holdings in Axon Enterprise by 8.2% in the 4th quarter. Chicago Capital LLC now owns 23,358 shares of the biotechnology company’s stock worth $13,882,000 after buying an additional 1,775 shares during the last quarter. Zweig DiMenna Associates LLC acquired a new stake in Axon Enterprise in the 4th quarter worth about $4,606,000. Finally, Cornerstone Wealth Management LLC acquired a new stake in Axon Enterprise in the 4th quarter worth about $260,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AXON has been the topic of several research analyst reports. Needham & Company LLC lifted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Craig Hallum cut Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. The Goldman Sachs Group boosted their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th. Barclays boosted their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. Finally, Northcoast Research cut Axon Enterprise from a “buy” rating to a “neutral” rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $652.73.

Axon Enterprise Stock Up 1.2%

AXON stock opened at $742.32 on Tuesday. The firm has a market cap of $57.79 billion, a PE ratio of 191.81, a PEG ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm’s 50 day moving average price is $588.30 and its 200-day moving average price is $597.92. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $742.34.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business’s revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 EPS. On average, equities research analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Activity

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares of the company’s stock, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeri Williams sold 307 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares in the company, valued at approximately $899,275.44. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,764 shares of company stock valued at $14,856,635. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.